Recently, Shenzhen Eurekabio Technology Co., Ltd. (hereinafter referred to as "Eurekabio") announced that it had completed the 100 million CNY of round B financing. This round of financing is led by Eight Roads Capital, followed by Shenzhen Jiufite Private Equity and Juke Investment, followed by Danaher, Galaxy Capital acts as the exclusive financial adviser.

Eurekabio currently has multiple business segments. In its upstream equipment R & D business segment, one of its core products is the fully enclosed automatic cell processing system Cellsep ® PRO (CSP for short) is applicable to the standardized production of a variety of cell therapy products. It has helped leading enterprises in many cell therapy (including CAR-T, TCR-T, CAR-NK, TIL, stem cell drugs, etc.) to complete IND application, clinical phase I and phase II trials. Another core business segment is lentivirus vector production system based on stable cell lines. This technology breaks through the technical bottleneck of large-scale production of lentivirus vectors, greatly improves the production efficiency and product consistency of lentivirus vectors, and reduces the production, promotes the innovation of virus vector production technology as well.

Relying on its multiple business segments and the continuous introduction of innovative equipment and technology, Eurekabio has helped the whole industry greatly reduce the process operation difficulty and production cost from the upstream supply, and helped Chinese people have affordable CGT solutions.

About Eureka Bio:

Founded in 2014, Eurekabio is a scientific and technological enterprise focusing on the research and development of core technologies and processes in gene and cell therapy. The company has committed to discovering innovation ways to in the field of life science through the interdisciplinary of computer science, electronic engineering, nanomaterials, chemical engineering with life science. It devoted to make life science and technology evolve rapidly, and solve a series of technical challenges in gene and cell therapy industry.